Forums and Workshops (April 30)
Forums and Workshops (April 30)
11.10 - Welcome and Introductions
Moderator: Zafar Aziz, Director, Head of Strategic Sales & DR Investor Relations Advisory Group, Deutsche Bank
11.15 – Opening Presentation – IPOs: what is the current state of the market and what should companies expect from their advisors?
Presenter: James Taylor, Co-Head of Investment Banking, Deutsche Numis
11.45 – Expert Panel Discussion – IPO opportunities: US vs UK?
- How is London is changing its rules to make it easier for companies to list?
- Is there a valuation difference between the UK and the US?
- Are you a small fish in a big pond if you choose the US?
- Is it better to be dual-listed?
- With the rise of passive funds, is indexation an important consideration?
- How should you approach investor relations if dual listed?
- Execution of listing: Necessary steps to prepare
- Life as a public company
Moderator: Zafar Aziz, Director, Head of Strategic Sales & DR Investor Relations Advisory Group, Deutsche Bank
James Taylor, Co-Head of Investment Banking, Deutsche Numis
Tim Davis, Regional Head, UK Primary Markets, London Stock Exchange
Isabella Schidrich, Senior Managing Director, NASDAQ
12.15 – Q&A and Discussion
14:00 - Welcome and Introductions
Moderator: Elizabeth Rhodes, Partner, Goodwin
14:05 - Raising capital to support later-stage growth
- Market Update – Later stage rounds are challenging to get away and IPO market increasingly pressurising the valuations of private companies.
- Valuation Pressure – dangers of structuring preference rights to prop up a higher valuation / avoid a down round.
- How to continue to incentivisation when there is an increasing liquidation preference.
- How to set yourself up for a successful exit
Elizabeth Rhodes, Partner, Goodwin
Kenny Walker-Durrant, Partner, Goodwin
14:40 - CEO-Led Case Study
15:00 - CEO-Led Case Study
15:20 - General Discussion and Q&A
15:40 - End of Forum
The M&A workshop led by Hogan Lovells will consider the different means through which early/late stage biotech and pharma assets can be most effectively monetised, including through M&A, collaboration/JV and licensing structures.
The workshop will consider the pros and cons of each structure from both a seller’s and buyer’s/investor’s perspective. The format will be interactive and factor in current trends (e.g. the increased use of AI and integration of healthcare services into technology platforms) and growth products and therapies (e.g. ADC’s, RLT’s, GLP-1, health span and pre-emptive medicine and chronic/orphan disease).